University of the Ryukyus · Faculty of Medicine

Research keywordsadipose-derived stem cells・mesenchymal stem cells・spinal cord injury・knee osteoarthritis・dental pulp stem cells・chronic wound healing・extracellular vesicles・regenerative medicine

This is a public-data preview. Personalized fit, contact angles, and saved workflows require sign-in.

• A novel cell source for therapy of knee osteoarthritis using atelocollagen microsphere-adhered adipose-derived stem cells: Impact of synovial fluid exposure on cell activity2024 · INTRODUCTION: Administration of adipose-derived stem cells (ADSCs) into the joint cavity has been shown to alleviate the symptoms of knee osteoarthritis (OA) by releasing exosomes and anti-inflammatory cytokines. However, the therapeutic effect of these cells is limited by their rapid disappearance after administration. Thus, it is necessary to prolong cell survival in the joint cavity. This study aimed to investigate the potential application of ADSCs adhered to atelocollagen microspheres (AMSs) for cell therapy of knee OA. METHODS: ADSCs were cultured for 2, 4, and 7 days in AMS suspension or adherent culture dishes. The supernatants were analyzed for IL-10 and exosome secretion via enzyme-linked immunosorbent assay and Nanosight. The effect of AMS was compared with that of adherent-cultured ADSCs (2D-cultured ADSCs) using transcriptome analysis. Moreover, the solubility of AMS and viability of ADSCs were evaluated using synovial fluid (SF) from patients with knee OA. RESULTS: Compared with 2D-cultured ADSCs, AMS-cultured ADSCs exhibited a significant increase in secretion of exosomes and IL-10, and the expression of several genes involved in extracellular matrix and immune regulation were altered. Furthermore, when AMS-cultured ADSCs were cultured in SF from knee OA patients to mimic the intra-articular environment, the SF dissolved the AMSs and released viable ADSCs. In addition, AMS-cultured ADSCs showed significantly higher long-term cell viability than 2D-cultured ADSCs. CONCLUSION: Increased survival of AMS-adhered ADSCs was observed in the intra-articular environment, and AMSs were found to gradually dissipate. These results suggest that AMS-adhered ADSCs are promising source for cell therapy of knee OA.
• Exploring SSEA3 as an emerging biomarker for assessing the regenerative potential of dental pulp-derived stem cells2024 · Shirakawa, J; Ntege, EH; Takemura, M; Miyamoto, S; Kawano, T; Sampei, C; Kawabata, H; Nakamura, H; Sunami, H; Hayata, T; Shimizu, Y
• Adipose-derived stem cell therapy for spinal cord injuries: Advances, challenges, and future directions2024 · Shimizu, Y; Ntege, EH; Takahara, E; Matsuura, N; Matsuura, R; Kamizato, K; Inoue, Y; Sowa, Y; Sunami, H
• Optimizing mesenchymal stem cell extracellular vesicles for chronic wound healing: Bioengineering, standardization, and safety2024 · Chronic wounds represent a significant global burden, afflicting millions with debilitating complications. Despite standard care, impaired healing persists due to factors like persistent inflammation and impaired tissue regeneration. Mesenchymal stem cell (MSC)-derived extracellular vesicles (EVs) offer an innovative regenerative medicine approach, delivering stem cell-derived therapeutic cargo in engineered nanoscale delivery systems. This review examines pioneering bioengineering strategies to engineer MSC-EVs into precision nanotherapeutics for chronic wounds. Emerging technologies like CRISPR gene editing, microfluidic manufacturing, and biomimetic delivery systems are highlighted for their potential to enhance MSC-EV targeting, optimize therapeutic cargo enrichment, and ensure consistent clinical-grade production. However, key hurdles remain, including batch variability, rigorous safety assessment for potential tumorigenicity, immunogenicity, and biodistribution profiling. Crucially, collaborative frameworks harmonizing regulatory science with bioengineering and patient advocacy hold the key to expediting global clinical translation. By overcoming these challenges, engineered MSC-EVs could catalyze a new era of off-the-shelf regenerative therapies, restoring hope and healing for millions afflicted by non-healing wounds.

• 多層化脂肪幹細胞シートを用いた肛門括約筋再生に関する研究2024 · 基盤研究(C)
• 再生医療等製品（Muse細胞製剤）の原材料としての歯髄細胞の可能性2024 · 基盤研究(C)
• 皮下膵島移植の成績を向上する3D膵島細胞シートの開発2024 · 基盤研究(C)
• エクソソームを用いた胸腹部大動脈術後対麻痺に対する新たな予防法の開発2022 · 基盤研究(C)

• Official profile